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KAJIAN MENGENAI FAKTOR-FAKTOR BIOKIMIA YANG MEMPENGARUHI 
KEMATANGAN AWAL PEMBULUH DARAH FISTULA 
ABSTRAK 
Terdapat peningkatan pesakit penyakit buah pinggang peringkat akhir yang memerlukan 
rawatan hemodialisis di seluruh dunia. Akses vaskular untuk rawatan hemodialysis kekal 
sebagai komponen utama, tetapi malangnya, penyelenggaraan akses ini masih menjadi 
cabaran utama. Tempoh kematangan arteriovenous fistula (AVF) adalah dipengaruhi oleh 
faktor-faktor pembolehubah seperti umur, kehadiran aterosklerosis , kalsifikasi vaskular dan 
penyakit mineral tulang.  
 Kajian ini bertujuan untuk menilai faktor-faktor yang mempengaruhi kematangan 
akses vaskular, termasuk penyakit sedia ada dan sosio demografi. Kajian retrospektif ini 
telah dijalankan di Pusat Sumber Penyakit Buah Pinggang Kronik, Hospital Universiti Sains 
Malaysia dari tahun 2004 hingga 2014. Satu ratus rekod perubatan pesakit yang telah 
menjalani pembedahan AVF terlibat dalam kajian ini, dengan tumpuan diberikan kepada 
faktor-faktor yang berkaitan dengan kematangan AVF. Pesakit hemodialysis yang berumur 
dua puluh lima tahun keatas, belum pernah menjalani prosedur yang melibatkan salur darah 
utama (central vein) dan  menjalani pembedahn AVF untuk kali pertama dimasukkan ke 
dalam kajian ini. Kriteria pengecualian adalah seperti penyakit vaskular periperal, stenosis 
salur darah vena utama, kecacatan pada bahagian tubuh untuk AVF dan penyakit vasculitis. 
 Di kalangan 100 pesakit yang dipilih, masing-masing mencapai tempoh kematangan 
awal dan lewat sebanyak 49 (49 %) dan 51 (51 %). Min (SD) umur untuk kematangan awal 
AVF adalah 58.51 (11.27%) tahun, manakala kematangan lewat AVF adalah 57.61 (0.89%) 
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tahun. Kebanyakan pesakit adalah tidak merokok dan bangsa Melayu. Di kalangan 
kematangan lewat AVF, 27 (52.8 %) adalah pesakit kencing manis dan 47 (92.2 %) adalah 
pesakit tekanan darah tinggi. Tiada perbezaan yang signifikan dalam produk kalsium and 
fosfat pada awal dan lewat kematangan AVF (nilai p: 0.092) ; walau bagaimanapun , nilai 
produk kalsium dan fosfat didapati lebih tinggi pada kumpulan yang mencapai tempoh 
kematangan yang lewat. Penyakit kencing manis, tahap HbA1c dan tahap LDL didapati 
dengan ketara mempengaruhi lewat kematangan AVF  dengan nilai p: <0.05 masing-masing. 
LDL didapati menjadi faktor peramal kematangan lewat ( nisbah ods: 2.63; 95% CI: 1.62, 
4.40; nilai p: < 0.001). 
 Kesimpulannya, pelbagai faktor mempengaruhi kematangan AVF. Penyakit kencing 
manis, tahap HbA1c dan tahap LDL didapati mempengaruhi kematangan AVF. Pesakit 
dengan kenaikan 1 g/dL LDL didapati menyebabkan lewat kematangan AVF sebanyak 2.67 
kali ganda. 
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ABSTRACT 
There has been an increasing trend of end stage renal disease patients requiring 
haemodialysis treatment worldwide. Vascular access remains the key component of 
haemodialysis treatment, unfortunately, the maintenance of this access remains a 
challenging problem. The maturity of arteriovenous fistula is influenced by variable factors 
such as age, presence of atherosclerosis, vascular calcification and bone mineral disease.  
This study is aimed to evaluate the biochemical factors that influence the vascular 
access, including comorbidities and the socio-demographics. This retrospective study was 
performed in Chronic Kidney Disease (CKD) Resource Center, Hospital Universiti Sains 
Malaysia between 2004 to 2014. One hundred medical records of patients underwent native 
arteriovenous fistula (AVF) creation were reviewed focusing on the associated factors and 
arteriovenous fistula maturity. Patients above 25 years old with chronic kidney disease stage 
4 and above, with no previous intervention of the central vein and for first time AVF 
creation were included in this study. Exclusion criteria included periperal vascular disease, 
central venous stenosis, vascular access site deformity and vasculitic disease.  
 Among the selected 100 subjects, 49 (49%) and 51 (51%) achieved normal and 
delayed maturation respectively. The mean (SD) age for normal AVF maturation was 
58.51(11.27%) years, while delayed arteriovenous maturation was 57.61 (0.89%) years. 
Majority of the subjects were non-smoker and Malay. Among delayed AVF maturation, 27 
(52.8%) were patients with diabetes mellitus and 47 (92.2%) were patients with 
hypertension. Calcium phosphate product was insignificantly associated with delayed AVF 
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maturation (p-value: 0.092); despite higher mean (SD) calcium phosphate product was 
observed in delayed mature AVF than normal mature AVF group. Diabetes mellitus, HbA1c 
and LDL were found to be associated with delayed AVF maturation with p-value < 0.05 
respectively. Whereas, LDL has statistical significance at the level of multivariable analysis 
in delayed AVF maturation with adjusted OR of 2.67 (95% CI: 1.62, 4.40); p-value < 0.001. 
 In conclusion, impact on AVF maturation is multifactorial. Diabetes mellitus, HbA1c 
and LDL were found to be associated with delayed arteriovenous fistula maturation. A 
Chronic Kidney Disease subject who has increasing LDL level by 1 g/dL has 2.67 times of 
delayed AVF maturation.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Research Background  
 
Fresenius Medical Care in 2012 showed globally by end 2012,  3,010,000 patients are being 
treated for ESRD and, with a ~7% growth rate, this figure continues to increase significantly 
higher rate than the world population. The growth of ESRD patients is five times the world 
population growth (1.3%) and continues growing beyond all normal expectations, showing 
no signs of reaching a steady state within the next two decades (Moeller et al., 2002). 
Factors contributing to this growth include globally ageing, multi-morbid population, higher 
life expectancy of treated ESRD patients and increasing access of a generally younger 
patient population to treatment. This disease present a significantly challenge to 21st century 
global health policy. 
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       ( Fresenius Medical Care 2012) 
 
Figure 1: Development of global ESRD and dialysis prevalence value since 2000 ( patients 
per million population) 
 
 Renal replacement therapy (RRT) remains the most important tool for all patients 
with end stage renal disease (ESRD) to support their life expectancy. There are 
haemodialysis, peritoneal dialysis or renal transplantation. Dialysis continues to be the most 
frequent type of RRT because of the low rate of renal transplantation, strictly related to 
insufficient organ donation to meet demand. As a consequence, there is increasing demand 
of haemodialysis among ESRD patients and arteriovenous fistula (AVF) is widely regarded 
as the gold standard of vascular access. In 1997 (updated in 2001), The National Kidney 
Foundation Dialysis Outcomes Quality Initiative (DOQI) proposed guidelines that AVF be 
constructed in at least 50% of permanent hemodialysis access procedures, to improve quality 
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of life and outcome in patients with end-stage renal disease. An additional DOQI goal was to 
achieve an AVF prevalence of 40% in all hemodialysis patients.  
 
 AVFs are widely regarded as the preferred vascular access in hemodialysis patients 
due to their primary patency and patient survival beneﬁts. The prevalence of fistulas among 
hemodialysis patients reflects both national, regional, and local practice differences as well 
as patient-specific demographic and clinical factors. Increasing fistula prevalence requires 
increasing fistula placement, improving maturation of new fistulas, and enhancing long-term 
patency of mature fistulas for dialysis. Fistulas have been identified as the best outcome and 
can be placed with the least expense and complication rate when compared to a catheter or 
graft. Therefore, regional and network indicators promote the placement of AVF. Several 
recent initiatives have focused on vascular access and ways to improve outcomes. The 
National Foundation for Kidney Dialysis Outcomes Quality Initiative (K-DQOL), End Stage 
Renal Disease Clinical Performance Measures (CPM) and Fistula First Initiative (FFI) have 
provided guidelines that mandate fistula access in patients on hemodialysis (Vasquez, 2009).  
 
Whether a patient receives a fistula depends on several factors: timing of referral for 
dialysis and vascular access, type of fistula placed, patient demographics, preference of the 
nephrologist, surgeon, and dialysis nurses, and vascular anatomy of the patient (Allon and 
Robbin, 2002). Vascular access should be easy to use, reliable and have minimal risk to the 
individual receiving haemodialysis. The ideal vascular access should provide safe and 
effective therapy by enabling the removal and return of blood via an extracorporeal circuit. It 
also improved morbidity, mortality and cost-effectiveness.  
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 As the number of newly diagnosed end stage renal disease increases, the demand for 
hemodialysis grows proportionately. The arteriovenous fistula is preferred for long-term 
hemodialysis vascular access since it has the best long-term primary patency rate, requires 
the fewest interventions of any type of access and most importantly, AVF are associated 
with the lowest incidence of morbidity and mortality. Once a fistula is created, it must 
develop to the point that it is usable. For maturation to occur, the main principal is vessel 
remodeling. This means that AVF must be of adequate size to allow for successful repetitive 
cannulation and provide blood flow to support the hemodialysis prescription. 
 
Based on United States Renal Data System (USRDS), AVF prevalence has risen to 
42% as of June 2006. The unanticipated consequence of aggressive AVF placement is the 
high proportion of AVFs failure to mature. Approximately 25-30 years ago, only 10% of 
new AVFs failed to mature, in subsequent years, it has increased to 20-50% (Allon and 
Robbin, 2002). Hence, there is a challenging issue need to maintain a good quality access as 
the fundamental of the treatment of haemodialysis treatment. 
 
 AVF non-maturity has emerged as the major obstacle to dialysis patients. Fistula 
failure may be classified as primary defined as a fistula, which fails prior to cannulation and 
secondary, defined as failure after a radiologic intervention such as angioplasty or stent or 
surgical revision (Hammes, 2011). It is well known from several studies that there is a 
significant primary failure rate for all AV fistulas that are placed (Schild, 2004; Biuckians, 
2008; Dember 2008). Causes of normal fistula failure are due to inflow problems from 
inadequate arterial supply, anastamotic stenosis which may result from trauma during 
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creation, or outflow problems of the venous segment. Outflow problems may occur because 
of underlying fibrosis of the vein (Hammes, 2011).  
 
 Numerous studies have been performed in the attempt to correlate the factors 
responsible for failure of the AVF maturity. Various predicting factors have been studied in 
this matter and the understanding of the pathogenesis of AVF nonmaturation is imperative to 
achieve the KDOQI AVF goals. The importance of identifying potential patient factors 
predisposing to failure of AVF maturity may provide opportunities in improving dialysis 
vascular access outcomes. This will guide clinicians to decide the optimal timing and patient 
selections on vascular access creation. Thus will benefit patients and reduce potential 
complications from the unfavorable surgical interventions.  
 
 Various clinical factors will be identified, including patients’ demographic factors, 
comorbidities and biochemical factors related to the Delayed of AVF maturity. In view of 
disturbances in mineral and bone metabolism are common complications in CKD; they will 
be the alarming factor in influencing the arteriovenous fistula maturation with the risk of 
vascular calcification and reduced arterial compliance (Moe and Chen, 2004).  
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1.2 Rationale Of The Study 
 
This study is designed to correlate between the association factors and the delayed 
arteriovenous fistula maturation in chronic kidney disease patients in HUSM. The main 
focus of this study is to evaluate the influence of sociodemographic data, comorbidities and 
biochemical factors on the arteriovenous fistula maturity. Since there is high prevalence of 
delayed arteriovenous maturation and yet the factors were not well known, we hope that 
with this study, it will provide valuable information on the factors in influencing the 
arteriovenous fistula maturation and enable us to improve the outcome of fistula.  
 
 Besides, the results of this study may help in identifying the predictor factors of 
delayed arteriovenous fistula maturation, hence justification for the execution of this study is 
for the purpose of achieving effective vascular access in CKD patients requiring 
heamodialysis. In a long term, this will improve the cost effectiveness of AVF placement 
and at the same time, reduce the unwanted complications.  
 
 The benefits of this study are to provide local data in HUSM and develop new 
information about the associated factors with delayed arteriovenous fistula maturation. 
Hopefully with the information gained, it provides a guide for the selection of patients in 
vascular access placement and subsequently prevents unnecessary failure. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Factors Affecting Arteriovenous Fistula Maturation 
 
Arteriovenous fistula (AVF) creation is feasible in majority of cases including diabetics and 
elderly patients. However, thrombosis and/or delayed in maturity are reasons of primary 
AVF failure, however risk factors for primary failures are not limited to the site and vascular 
diameters (Rodriguez et al., 2000). A study conducted from 1997 to 1999 showed the 
primary failure rate between 10-20% (Pavcnik et al., 2008). A recent meta-analysis has 
demonstrated 15.3% primary failure rate for native AVF (Irish et al., 2009). Several studies 
provided insights into the problem of AVF delayed maturity unfortunately there is a 
relatively limited understanding of why fistulas fail.  
 
 The maturity of AVF influenced by multifactorial, pietro ravani et al., 2004 stated 
that the important finding of  the  study is the negative effect of cardiovascular disease on 
AVF survival. In the present series, presence of cardiovascular disease conferred 83% and 
two fold increase in probability of primary and final AVF failure, respectively. The 
explanation for this may be complex and multifactorial. Whether the presence of 
cardiovascular disease has a direct effect on AVF maturation and survival or is simply a 
marker of severe comorbidity, poor predialysis care, or uncontrolled uremia cannot be ruled 
out from the database (Ravani et al., 2004).  
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  Delayed maturation of fistulas will lead to prolonged dependence on dialysis 
catheters. This phenomenon is well known to be associated with the risk of infection, central 
venous thrombosis or stenosis and social inconvenience to the patients. There has been 
numerous studies on the correlative factors to the late maturation of fistulae; however, each 
study has its own limitation, end points and clinical factors consideration. Identifying the 
risk factors in delaying maturation or fistulae failure will help the clinicians in selecting 
suitable patients at good timing. 
 
2.1.1 Sociodemographic Factors  
 
Factors which contribute to the primary failure of fistulas include demographic factors such 
as age, obesity, non-white ethic group, female sex , history of diabetes or peripheral vascular 
disease (Lok, 2006; Huijbregts, 2008). The association between increasing age and greater 
risk for fistula maturity is consistent with the underlying need for adequate vessels, which 
deteriorate with the normal aging process and are damaged by concurrent disease (Feldman 
et al., 2003). Female has been described as a factor that decreases the likelihood of having 
an AVF placed as vascular access however, Feldman et al., 2003 stated that they did not find 
an association between sex and AVF maturation. Similar finding by Charmaine et al.,2006 
stated that the study did not find female gender to be associated with failure to mature. Many 
studies have given conflicting reports on the impact of these factors on the success of the 
AVF. Thus, further analysis of the factor would need to be advocated. 
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2.1.2 Diabetic Mellitus 
 
CKD patients often have factors other than kidney failure that may affect their vasculature, 
and it is possible that individual patients’ blood vessels may respond differently to the same 
hemodynamic stresses. This could be attributed to heterogeneity in the vascular wall 
biology, including endothelial function and clinical factors such as age, diabetes and stages 
of CKD (Fitts et al., 2014). For example, it is known that diabetes leads to increased arterial 
stiffness and therefore compromise the ability of the feeding artery to expand following an 
AVF creation surgery. The pathogenesis of arterial stiffness has been mention specifically 
related to endothelial dysfunction, indicated by impaired endothelium dependent 
vasodilation and increased plasma concentrations markers of endothelial function. Among 
important molecules synthesized by endothelial cells is nitric oxide, which is important 
endothelium derived mediator. Due to the impairment of vasodilatation, hence compromise 
the expansibility of the feeding artery to expand following an AVF creation surgery (Fitts et 
al., 2014).  
 
 The nature of the pathogenic link between high ambient glucose concentrations 
and diabetic complications remains a matter of debate, but clnormal hyperglycaemia is 
recognized as the primary culprit in the pathogenesis of diabetic complications. There is 
evidence showed that hyperglycaemia induces repeated acute changes in intracellular 
metabolism (activation of polyol pathway, activation of diacylglycerol-protein kinase C, 
increased oxidative stress), as well as cumulative long-term changes in the structure and 
function of macromolecules through formation of advanced glycation end products (AGEs) 
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(De Vriese et al., 2000). Hence, it is concluded that endothelium-dependent vasodilatation as 
a marker of endothelial dysfunction, which plays a key role in the pathogenesis of diabetic 
vascular disease (De Vriese et al., 2000). This is well explained by the diagram as below. 
 
 
        (British journal of pharmacology)  
 
 It is known that blood vessels from diabetic and non diabetic CKD patients may 
react to the same arteriovenous flow differently. However, Lok et al., 2006 stated that the 
study did not find diabetes a predictor of failure to mature. Indeed, diabetes is associated 
with suboptimal veins leading to poor fistula adequacy has been described in the study (Lok 
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et al., 2006). The presence of several comorbidities were associated with failure of the AVF 
to mature; these included history of hypertension, myocardial infarction, or coronary artery 
bypass surgery; cerebrovascular events; and thrombophlebitis or pulmonary embolism 
(Feldman et al., 2003).  
 
2.1.3 Hypertension And Atherosclerosis 
 
Abnormalities of the endothelium underlie a number of human diseases and appear to be 
central to the pathogenesis of atherosclerosis. Changes in endothelial function and 
morphology are also cardinal features of hypertension. When there is an increase in blood 
pressure, it causes ongoing adaptive responses in the microvasculature. There have been 
observed that, increase vascular smooth muscle cell growth is another common feature in the 
pathogenesis of both atherosclerosis and hypertension. The growth of vascular smooth 
muscle is controlled to an important extent by the endothelium. The normal endothelium 
appears to exhibit an inhibitory influence on vascular smooth muscle cell growth. When 
there is either atherosclerosis or hypertension, dysfunctional endothelium happened and may 
contribute to or permit vascular smooth cell growth, which contributes to narrowing of the 
lumen. Hence, influencing the vasculature dilatation as part of the cardinal phenomena in 
fistula maturity.  
 
  There is evidence suggest that atherosclerosis and hypertension each may enhance 
the oxidative stress of the arterial wall (Alexander, 1995). It has also been suggested that 
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superoxide anions might trigger the development of hypertension in some experimental 
models, presumably by inactivating endothelium-derived nitric oxide and thus mitigating 
this important vasodilator mechanism. Thus, hypertension facilitates the development and 
progression of atherosclerosis as such it oxidatively stresses or injures the endothelium, 
resulting in activation of redox-sensitive mechanisms that recruit mononuclear leukocytes 
into the arterial wall (Alexander, 1995). 
 
 Another effect of hypertension on the arterial wall was shown as the increased wall 
stress resulting in arterial stiffening. Arterial stiffening occurs due to the loss of compliance 
of the vascular wall. This is linked to a disequilibrium of its two prominent scaffolding 
proteins that are collagen and elastin, with the overproduction of abnormal collagen and 
diminished quantities of elastin. The principal pathophysiological consequence of arterial 
stiffness is decreased arterial distensibility. Endothelial function affects arterial stiffness 
through influencing vascular smooth muscle cell tone. The dilator effects of endothelium are 
under the control of the activity of the endothelial nitric oxide synthase. Nitric oxide plays a 
crucial role in vascular protection because it inhibits proliferation and migration of VSMC, 
expression of adhesion molecules, and platelet aggregation (Channon et al., 2000). Thus, the 
lack of availability of nitric oxide is a major factor in the occurrence of atherosclerosis.  
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2.1.4 Adequacy Of Vessels And Types Of Arteriovenous Fistula (AVF)  
 
 In order for as AVF to mature, there must be sufficient delivery of intra-access blood flow 
and pressure, depending upon on adequate cardiac output/ systemic blood pressure. A good 
quality feeding (arterial) vessel is mandatory, which will be able to transmit a high pressure 
to an accepting, unrestricted (i.e. no anastomotic stenosis), compliant and distensible outflow 
(venous) vessel (Lok et al., 2006). Thus, for an AVF to mature, it needs sufficient flow 
through the fistula to support hemodialysis and preventing thrombosis. Adequacy of the 
fistula flow rate depends on the pressure gradient and the total resistance in the fistula circuit 
including the proximal artery, fistula anastomosis, and the downstream vein. Hence, both 
coronary artery disease and peripheral vascular disease were predictors of failure to mature, 
each indicating diseased inflow and outflow in reference to the anastomosis, respectively.  
 
 Haemodialysis patients have vascular properties that impair dilatation. Their arteries 
may develop increased intimal and medial thickening, medial calcification and increased 
stiffness with decreased flow-mediated dilatation. Artery is generally narrower than the vein 
hence, the artery is the chief source of vascular resistance in a new fistula. Thus, arterial 
dilatation plays an important role in fistula maturation. These observations have led to 
suggestions that vascular compliance should be assessed preoperatively. So far, there are 
many factors influencing the maturation of fistula and one of the commonest cause is arterial 
elasticity (Morad, 2012).  
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 AVF have a relatively high rate of primary failure, due to either normal thrombosis 
or failure of the draining vein to dilate adequately to mature. The rate of primary failure may 
be substantially higher in forearm, as compared to upper arm fistulas. Primary failure rate 
has been reported as 66% in forearm fistulas, as compared with 41% among upper arm 
fistulas (Allon et al., 2001). Similarly, Hakaim, Nalbandian and Scott observed a 70% non-
maturation rate for forearm fistulas among diabetic dialysis patients, as compared with 22% 
for upper arm fistulas (Ethier et al., 2008). In the recent study done in Alor Setar, it 
concludes that established peripheral arterial disease, distally placed fistula, lower mean 
arterial pressure and absence of post operative immediate thill were significantly associated 
with premature failure of autogenous AVF (Najmi et al., 2012). 
 
 The fistula with the best outcome is the lower arm radiocephalic (RCF); however this 
access often fails to mature in the elderly patient with underlying vascular disease, 
particularly in diabetics (Miller,1999; Rodriquez, 2000). The second recommended fistula is 
the upper arm brachiocephalic fistula (BCF). This type of fistula is being placed with 
increased frequency because of the high failure rate of RCF. The third recommended fistula 
is the brachiobasilic fistula (BBF), which usually involves a two step surgical procedure and 
may be difficult to cannulate given the medial location of the basilic vein.  
 
 Based on multiple previous studies, we can conclude that distally placed fistula has 
higher primary failure rate than proximal placed fistula. It is likely associated with the 
anatomically larger diameter and feasible vessels in the proximal of the upper arm.  
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2.1.5 Calcium Phosphate Product On Vascular Calcification  
 
The presence of increased vascular calcification in patients with CKD has been known, 
however the extent to which vascular calcification impacts on cardiovascular disease and 
mortality has recently been appreciated. Studies have reported increased coronary artery 
calcification and the extent of vascular calcification in CKD compared with the general 
population. There is a relationship between increased vascular calcification and loss of bone 
mineral content, with recent experimental studies revealing the mechanisms link these two 
processes (Davies and Hruska, 2001; Moe, 2006).  
  
The mechanisms of vascular calcification in CKD and ESRD remain an active area 
of research. Vascular calcifications classically occur in two locations, the intima and the 
media. Intimal calcifications are part of the atherosclerosis process. They are limited to large 
and medium-sized conduit arteries. Although they are not specific to CKD, calcifications of 
coronary arteries are twofold to fivefold more frequent in CKD patients than in age-matched 
individuals with angiographically proven coronary artery disease (Reynolds et al., 2005). 
Medial calcifications occur in elastin fibers around vascular smooth muscle cell (VSMC) in 
the absence of atherosclerosis and are seen primarily in CKD or diabetes. 
 
 Local and systemic calcium-regulatory proteins as well as inhibitory extracellular 
factors are also involved in the pathogenesis of vascular calcification. Vascular calcification 
is the end result from an imbalance between cellular mediators which promote and inhibit 
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mineralization. In addition to proper homeostasis of vascular mineralization, the current 
research to date has demonstrated that one major mechanism involved in regulation of 
vascular calcification is vascular smooth muscle cell (VSMC) damage (Shroff and 
Shanahan, 2007). Normally, VSMCs play an important role in inhibiting calcification, but in 
pathologic environments such as kidney disease their normal function is compromised and 
they develop osteogenic phenotypic changes that favor deposition of minerals that leads to 
calcification (Shroff and Shanahan, 2007). It is also hypothesized that when VSMCs become 
apoptotic, they release apoptotic bodies which accumulate calcium and initiate the 
calcification process (Proudfoot et al., 2000; Shroff and Shanahan, 2007; Shroff et al., 
2008). Furthermore, VSMCs have been reported to bud matrix vesicles from their plasma 
membranes. These small membrane bound particles form a microenvironment capable of 
concentrating calcium and phosphate and allowing for crystal nucleation (Proudfoot et al., 
2000; Reynolds et al., 2004; Shroff and Shanahan, 2007). 
 
In patients with chronic kidney failure, increased serum calcium phosphate product 
and hyperphosphatemia are important contributors to the higher incidence of arterial 
calcifications and cardiovascular events. Hyperphosphatemia, by accelerating the 
progression of secondary hyperparathyroidism, increases serum PTH and bone loss. High 
PTH itself induces increases in intracellular calcium and abnormal lipid metabolism that 
promote soft tissue calcifications. Phosphorus-induced and PTH induced bone loss elevates 
calcium phosphate product and, most likely, the expression of factors that mediate the strong 
association between bone loss and arterial calcification, such as bone-associated proteins.  
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Direct effects of phosphorus on vascular pathology include the regulation of vascular 
cell proliferation as well as the induction of the expression of the osteoblast-specific bone-
forming proteins, Cbfa-1 and osteocalcin. Clnormal, the control of serum phosphorus levels 
in patients with uremia may reduce vascular calcification not only by decreasing calcium-
phosphate product but also by reducing serum PTH, thus ameliorating the active and yet 
incompletely understood processes common for vascular calcification and bone loss. In the 
last 10 years, several mechanisms have been proposed for phosphate regulation of vascular 
calcification, involving not only deposition of calcium and phosphate in the vasculature, but 
also direct activation of genes associated with osteoblastic functions in vascular smooth 
muscle cells (Jakoby IV and Semenkovich, 2000).  
 
 Recent studies have demonstrated phosphate regulation of vascular calcification 
and provided some insights into the mechanisms for phosphate induction of metastatic 
calcifications. In vivo studies by Kuro-o et al., in the KLOTHO-gene mutant mice with a 
phenotype that resembles human aging, demonstrated that, in the presence of normal serum 
creatinine, albumin, cholesterol, and triglyceride levels and with only a mild increase in 
serum calcium levels (from 9.5 to 10.6 mg/dl), a two-fold increase in serum phosphate levels 
resulted in increased calcium-phosphate product as well as the development of vascular 
calcifications and osteoporosis that were clnormal unrelated to malnutrition, abnormal lipid 
metabolism, or chronic renal failure (Kurosu et al., 2005). Hyperphosphatemia was the main 
determinant of the increased calcium phosphate product. In the study by Jono et al., 2000 
which assessed the contribution of hyperphosphatemia per se on vascular calcification, the 
study demonstrate that, high phosphorus levels in the incubation media (2 mmol/L 
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phosphate) enhanced calcification in human aortic smooth muscle cells. In conclusion, 
elevation of calcium phosphate product and  high phosphate per se could induce vascular 
calcification.  
 
 The calcium crystal that accumulates in the vasculature and contributes to vascular 
calcification is calcium apatite, which is the mineral found in bone, and the discovery of 
bone-related factors in vessels when calcified adds stronger evidence to the intimate 
relationship between bone disorder and vascular calcification. With high bone turnover, 
associated with elevated parathyroid hormone (PTH) levels, the egress of phosphate from 
bone is increased and this condition is associated with increased vascular calcification. There 
are many studies have been reported a positive relationship between vascular calcification 
and serum calcium, phosphate and calcium phosphate product. Vascular calcification, 
induced by calcium and phosphate excess and uraemia, is a major risk factor and is 
independently associated with cardiovascular events and death. This well demonstrated in 
the Figure 3 as follow. The optimal control of mineral metabolism, especially 
hyperphosphatemia with non-calcium based phosphate binders, has been shown to be 
effective to reduce vascular calcification, and attenuation of arterial stiffness (Toussaint and 
Kerr, 2007). 
 
 
  19 
 
Figure 3: Impact of hyperphosphatemia on vacular calcification 
 
 Vascular calcification, previously thought to be precipitation of excess minerals at 
sites of damage, is now recognised as an active process involving a complex interaction of 
inducers and inhibitors with dysregulation of the normal equilibrium, as in CKD, resulting in 
the development of vascular calcification. The extent of vascular calcification and the degree 
of arterial stiffening, closely interrelated are independent predictors of cardiovascular 
mortality in both the general and CKD populations. There is emerging evidence that 
vascular calcification is an active cell-mediated process, exacerbated by both uraemia and 
abnormalities in mineral and bone metabolism and it has been well reported that increased 
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serum levels of calcium, phosphate and PTH are associated with increased mortality as well 
as greater vascular calcification (Toussaint and Kerr, 2007).  
 
 The calcium–phosphorous product is considered a theoretical indicator of the risk 
of mineral crystallization in soft tissues. However, as deposition and dissolution of calcium 
salts is a dynamic process, there is no absolute level of calcium–phosphorous below which 
precipitation will not occur. KDIGO CKD MBD 2009, indicated a threshold product of   
4.18 mmol²/L² based on a comparison of patients with and without visceral calcifications, 
suggesting that this level represents the saturation product of the two ions.  
 
 Velentzas et al. mentioned that inflammation might trigger calcium deposition in 
the arteries. In this context it should also be considered that CRP, being a member of the 
pentraxin family, binds to damaged tissue in a calcium dependent manner and shows 
membrane association with multiple calcium ions. Moreover, CRP binds to enzymatically 
degraded LDL (E-LDL) particles in normal atherosclerotic lesions, inducing complement 
activation and promoting the development and progression of the atherosclerotic lesion. 
There is a general consensus about CRP being a marker of cardiovascular risk both in non-
uraemic  and uraemic subjects. It could also be a promoter of the progression of 
atherosclerotic lesions.  
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2.1.6 Uremia 
 
Many studies have shown the involvement of uremic toxins and endothelial dysfunction in 
several aspects of uremic atherosclerosis. Endothelial dysfunction is especially significant in 
end stage renal disease (ESRD) population due to the negative impacts of uremia and 
oxidative stress on the endothelium (Hammes, 2011). Indeed, endothelium-dependent 
vasodilation has been found to be markedly impaired in chronic hemodialysis patients 
(Hammes, 2011). Vascular dysfunction due to chronic uremia in CKD patients can be 
delineated into four categories, reviewed by Brunet P et al., 2011 stated that (a) increased 
rate of atherosclerosis, (b) increased arterial stiffness, (c) increased formation of vascular 
calcifications, and (d) impaired vascular repair and increased neointimal hyperplasia 
formation. Uremia is associated with a range of elevated toxins, including guanidines, 
advance glycation end products (AGE), p-cresyl sulfate, platelet diadenosine 
polyphosphates, and indoxyl sulfate (Brunet et al., 2011). These toxins are associated with 
increases in arterial stiffness, calcification, impaired vessel wound healing responses, and 
neointimal hyperplasia (Brunet et al., 2011). Increased asymmetric dimethyarginine 
(ADMA) and AGE leads to a decrease in nitric oxide bioavalibility, leading to impaired 
dilatory function of arteries, as well as impaired signaling for nitric oxide-related processes 
such as wound healing (Fitts et al., 2014). Thus, blood vessels from CKD patients may react 
to the same arterioveneous flow differently, depending on the endothelial damages by 
uremia. 
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Arterial vascular histologic changes and remodeling occur in response to increasing 
hemodynamic alterations and increasing uremia from progressive CKD. The arterial 
vascular pathology associated with CKD and ESRD is commonly characterized by the 
presence of significant intimal and medial calcification (London, 2003). In addition to CKD 
and ESRD, calcification has also been associated with increasing age, hypertension, 
diabetes, dyslipidemia, and smoking (Guérin et al., 2000). These changes to the vasculature 
from uremia and complications of advanced CKD may potentially effect the vascular access 
maturity and development of future stenosis. Thus, there has been a tremendous interest in 
developing therapies to reduce, minimize, and treat vascular development and 
complications, which may also have implications to vascular access creation and functional 
use.  
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2.2 Assessment Of Arteriovenous Fistula (AVF) Maturation  
 
Several changes are critical for successful maturation of a new AVF. There must be 
adequate dilatation of vessels to a caliber large enough to be cannulated repeatedly with two 
large bore dialysis needles. Furthermore, the blood flow rate in the draining vein must 
increase sufficiently to accommodate the dialysis blood flow required to deliver adequate 
dialysis. To avoid vein collapse and recirculation, the access blood flow should exceed the 
desired dialysis blood flow by at least 100 mL/min. The mean dialysis blood flow varies 
substantially among countries: about 400 mL/min in the United States, 300 mL/min in 
Europe, and 200 mL/min in Japan (abstract; Dykstra et al, J Am Soc Nephrol 11:182A, 
2000). These differences also mean that the definition of a mature fistula can vary among 
countries. Finally, the fistula must be superficial enough for the landmarks to be appreciated 
and permit safe cannulation without infiltration.  
 
 There is marked variation in the published literature regarding the definition of a 
successful fistula. The definitions have included presence of a thrill or bruit, ability to use 
the fistula for at least one dialysis session, or ability to use the fistula reproducibly for 
dialysis for at least one month with a dialysis blood flow > 350 mL/ min. 
 
 Fistula maturation is usually assessed subjectively by means of physical examination. 
A mature fistula will typically have an easily palpable superficial vein of adequate diameter 
that facilitates easy cannulation. It will have a uniform thrill to auscultation and palpation 
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that indicates adequate blood flow without stenosis. The accessible draining vein needs to be 
more than 10 cm long to allow for rotation of needle sites and adequate distance between the 
cannulating needles. If the draining vein is too tortuous or too deeply located in the 
subcutaneous tissues, it will be difficult to cannulate (Morad, 2012). 
 
 Timing of first cannulation of an arteriovenous fistula remains a controversial 
subject, but has been the subject of a few investigations reported in the literature recently. 
Data from DOPPS show that a functional fistula should have an outflow vein that can be 
successfully cannulated 1 month postoperatively.  
 
 According to National Kidney Foundation. Am J Kidney Dis. 2006;48(suppl 1):S1-
S322, the assessment for maturation of AVF by definition is by which a fistula becomes 
suitable for cannulation and the parameters included are volume flow, wall thickness, and 
vascular diameter. In general, a mature fistula should be a minimum of 6 mm in diameter 
with discernible margins when a tourniquet is in place, less than 6 mm deep from skin and 
have a blood flow greater than 600ml/min. As per the K/DOQI guidelines, all AVFs should 
be routinely evaluated at 4 weeks. By 4 weeks, normal postoperative edema will have 
resolved and it is expected that the majority of fistulae with have reached maximum flow. 
For evaluation for nonmaturation, it will be taken as 6 weeks after surgical creation if it does 
not meet the above criteria (Group, 2009).  
 
 
